Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

42.71 +0.23 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 704,520
Open 42.65
Bid (Size) 41.75 (1)
Ask (Size) 43.00 (2)
Prev. Close 42.48
Today's Range 42.10 - 43.07
52wk Range 32.69 - 47.74
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 7 Most Hated Stocks by Institutional Traders
Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future. 
Via InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,  
Via Benzinga

Performance

YTD
+13.65%
+13.65%
1 Month
+5.93%
+5.93%
3 Month
+9.23%
+9.23%
6 Month
+26.66%
+26.66%
1 Year
+2.30%
+2.30%

More News

Read More
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
Via Benzinga
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Via Benzinga
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
Via Talk Markets
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Via Investor's Business Daily
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Via Benzinga
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
Via Benzinga
Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday
Via Benzinga
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
Via Benzinga
What's Going On With Biogen Stock Tuesday?
Via Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Via InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.